ESSA Pharma Inc. — Director's Dealing 2024

Jan 18, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ESSA Pharma Inc. (EPIX)
CIK: 0001633932
Period of Report: 2024-01-16

Reporting Person: Virsik Peter (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-01-16	Common Shares	M	1718	$3.23	Acquired	15740	Direct
2024-01-16	Common Shares	S	1718	$10.01	Disposed	14022	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-01-16	Options	$3.23	M	1718	Disposed	2029-10-07	Common Shares (1718)	Direct

Footnotes

F1: Reflects a transaction effected pursuant to Mr. Virsik's 10b5-1 trading plan. The Rule 10b5-1 trading plan was entered into on August 31, 2023.

F2: The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.